DSM-5 and clinical trials in psychiatry: Challenges to come?

Nature Reviews Drug Discovery

Volumn 11, Issue 8, 2012, Pages 583-584

  Butlen Ducuing, Florence ^a   Haas, Manuel ^a   Pani, Luca ^b   Van Zwieten Boot, Barbara ^c   Broich, Karl ^d  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b ITALIAN MEDICINES AGENCY   (Italy)

^c MEDICINES EVALUATION BOARD   (Netherlands)

^d Federal Institute for Drugs and Medical Devices BfArM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; BIPOLAR DISORDER; COGNITIVE DEFECT; DISEASE DURATION; DISEASE SEVERITY; DSM-5; MAJOR DEPRESSION; MENTAL DISEASE; MIXED ANXIETY AND DEPRESSION; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PUBLICATION; RELIABILITY; RESEARCH PRIORITY; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; TREATMENT INDICATION; TREATMENT PLANNING; VALIDATION PROCESS;

CLINICAL TRIALS AS TOPIC; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DESIGN; HUMANS; LEGISLATION, DRUG; MENTAL DISORDERS; RESEARCH;

EID: 84864533347     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3811     Document Type: Review

References (5)

1. Regier, D. A. Dimensional approaches to psychiatric classification: refining the research agenda for DSM-V: an introduction. Int. J. Meth. Psychiatr. Res. 16, S1-S5 (2007).
2. Kraemer, H. C., Kupfer, D. J., Clarke, D. E., Narrow, W. E. & Regier, D. A. DSM-5: how reliable is reliable enough? Am. J. Psychiatry 169, 13-15 (2012).
3. First, M. B. DSM-5 proposals for mood disorders: a cost-benefit analysis. Curr. Opin. Psychiatry 24, 1-9 (2011).
4. Wakefield, J. C. DSM-5: proposed changes to depressive disorders. Curr. Med. Res. Opin. 28, 335-343 (2012).
5. Insel, T. R. & Wang, P. S. Rethinking mental illness. JAMA 303, 1970-1971 (2010).